NASDAQ
09.10.25 | 21:59
1,810 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.09. | BeyondSpring Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.08. | BeyondSpring Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| BEYONDSPRING Aktie jetzt für 0€ handeln | |||||
| 13.08. | BeyondSpring GAAP EPS of -$0.10 | 1 | Seeking Alpha | ||
| 13.08. | BeyondSpring Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.07. | BeyondSpring reports positive results for Plinabulin combination in ICI-resistant tumors | 1 | Investing.com | ||
| 07.07. | BeyondSpring, Inc.: BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure | 2 | GlobeNewswire (USA) | ||
| 03.07. | BeyondSpring plant Jahreshauptversammlung für den 15. September | - | Investing.com Deutsch | ||
| 03.07. | BeyondSpring Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.06. | BeyondSpring reports promising phase 2 NSCLC study results | 4 | Investing.com | ||
| 03.06. | BeyondSpring, Inc.: BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 12.05. | BeyondSpring GAAP EPS of -$0.08 | 2 | Seeking Alpha | ||
| 12.05. | BeyondSpring, Inc.: BeyondSpring Reports First-Quarter 2025 Financial Results and Provides Corporate Update | 190 | GlobeNewswire (Europe) | Presentation at IO 360° conference showed early efficacy for Plinabulin combinations in metastatic NSCLC and Hodgkin lymphoma resistant to PD-1/L1 therapySEED's first-in-class RBM39 degrader, reported... ► Artikel lesen | |
| 12.05. | BeyondSpring Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.05. | BeyondSpring Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.03. | BeyondSpring, Inc.: BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones | 189 | GlobeNewswire (Europe) | Plinabulin Final Phase 3 Data Published in The Lancet Respiratory Medicine, Demonstrating Overall Survival Benefit in 2L/3L NSCLC EGFR Wild Type vs. DocetaxelPlinabulin Phase 2 Data Highlights Potential... ► Artikel lesen | |
| 11.11.24 | BeyondSpring, Inc.: BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior ... | 192 | GlobeNewswire (Europe) | FLORHAM PARK, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company developing innovative cancer... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 53,21 | 0,00 % | Why Apogee Therapeutics Stock Triumphed on Thursday | ||
| IMMUNOVANT | 17,480 | 0,00 % | Immunovant Inc.: Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 20,710 | 0,00 % | Arcutis Biotherapeutics, Inc.: FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 | ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well toleratedOnce-daily, steroid-free cream can be used anywhere... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,905 | 0,00 % | Recursion Pharmaceuticals (RXRX) Climbs 16% Ahead of AI Conference | ||
| CABALETTA BIO | 2,850 | 0,00 % | Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress | ||
| VENTYX BIOSCIENCES | 3,860 | 0,00 % | Ventyx Biosciences, Inc.: Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson's Disease | The study met its primary goal of establishing safety and tolerability of VTX3232 in patients with early-stage Parkinson's disease CSF and plasma exposures reinforce VTX3232's potential as a once-daily... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 21,290 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update | Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 47% with 32% of patients achieving MMR by 24 weeks... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,870 | 0,00 % | Jefferies stuft Beam Therapeutics auf "Buy": Kommende Katalysatoren im Fokus | ||
| KYMERA THERAPEUTICS | 56,98 | 0,00 % | Stifel bestätigt Kaufempfehlung für Kymera Therapeutics vor wichtigen Studiendaten | ||
| ADMA BIOLOGICS | 14,745 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| ABSCI | 4,010 | 0,00 % | Absci Partners With Oracle And AMD To Accelerate AI-Driven Drug Discovery | SUNNYVALE (dpa-AFX) - Absci, a clinical-stage biotech focused on AI-powered therapeutics, announced a collaboration with Oracle Cloud Infrastructure - OCI and Advanced Micro Devices, Inc. (AMD)... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 39,430 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 10,680 | 0,00 % | Guggenheim initiates coverage on Olema Pharmaceuticals stock with Buy rating | ||
| CG ONCOLOGY | 44,410 | 0,00 % | Why Cg Oncology Stock Rocketed 7% Higher Today | ||
| DISC MEDICINE | 70,75 | 0,00 % | Mona Ashiya verlässt Verwaltungsrat von Disc Medicine - Gremium auf acht Mitglieder verkleinert |
Das Unternehmen BEYONDSPRING INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,810 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BEYONDSPRING INC finden Sie auf Wallstreet Online.